Basit öğe kaydını göster

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.

dc.contributor.authorKeskin, Dilek
dc.contributor.authorSadri, Sevıl
dc.contributor.authorEskazan, AHMET EMRE
dc.date.accessioned2021-03-04T12:43:28Z
dc.date.available2021-03-04T12:43:28Z
dc.identifier.citationKeskin D., Sadri S., Eskazan A. E. , "Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.", Drug design, development and therapy, cilt.10, ss.3355-3361, 2016
dc.identifier.issn1177-8881
dc.identifier.othervv_1032021
dc.identifier.otherav_78bd0345-e6fa-4846-b644-28c75a8a43dd
dc.identifier.urihttp://hdl.handle.net/20.500.12627/82793
dc.identifier.urihttps://doi.org/10.2147/dddt.s85050
dc.language.isoeng
dc.titleDasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.
dc.typeMakale
dc.relation.journalDrug design, development and therapy
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume10
dc.identifier.startpage3355
dc.identifier.endpage3361
dc.contributor.firstauthorID180288


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster